IMTX
$11.19
Immatics NV
$.65
6.17%
IMTX
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  ($0.35)
Revenue:  $14.85 Mil
Thursday
Feb 16
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when IMTX reports earnings?
Beat
Meet
Miss

Where is IMTX's stock price going from here?
Up
Flat
Down
Stock chart of IMTX
Analysts
Summary of analysts' recommendations for IMTX
Score
Grade
Pivots
Resistance
$11.98
$11.58
$11.39

$10.99

Support
$10.80
$10.40
$10.21
Tweet
Growth
Description
Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.